| Year |
Citation |
Score |
| 2023 |
Fasching PA, Szeto C, Denkert C, Benz S, Weber K, Spilman P, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, van Mackelenbergh M, et al. Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37014668 DOI: 10.1158/1078-0432.CCR-22-2213 |
0.584 |
|
| 2022 |
Bergamo F, Dalla Santa S, Loupakis F, Cerma K, Tosi A, De Grandis C, Dalla Pietà A, Gringeri E, Angerilli V, Ramondo G, Rago A, Cecchi F, Benz S, Cillo U, Dei Tos AP, et al. Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling. Frontiers in Oncology. 12: 964219. PMID 36578937 DOI: 10.3389/fonc.2022.964219 |
0.322 |
|
| 2022 |
Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, ... ... Benz SC, et al. Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer. Jco Precision Oncology. 6: e2100280. PMID 35294224 DOI: 10.1200/PO.21.00280 |
0.547 |
|
| 2021 |
Reimann H, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Niazi K, Rabizadeh S, Spilman P, Mackensen A, Ruebner M, Hein A, Beckmann MW, van der Meijden ED, Bausenwein J, Kretschmann S, et al. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. Journal For Immunotherapy of Cancer. 9. PMID 34172517 DOI: 10.1136/jitc-2021-002605 |
0.724 |
|
| 2020 |
Liu Y, Cook C, Sedgewick AJ, Zhang S, Fassett MS, Ricardo-Gonzalez RR, Harirchian P, Kashem SW, Hanakawa S, Leistico JR, North JP, Taylor MA, Zhang W, Man MQ, Charruyer A, ... ... Benz SC, et al. Single-Cell Profiling Reveals Divergent, Globally Patterned Immune Responses in Murine Skin Inflammation. Iscience. 23: 101582. PMID 33205009 DOI: 10.1016/J.Isci.2020.101582 |
0.313 |
|
| 2020 |
Newton Y, Sedgewick AJ, Cisneros L, Golovato J, Johnson M, Szeto CW, Rabizadeh S, Sanborn JZ, Benz SC, Vaske C. Large scale, robust, and accurate whole transcriptome profiling from clinical formalin-fixed paraffin-embedded samples. Scientific Reports. 10: 17597. PMID 33077815 DOI: 10.1038/s41598-020-74483-1 |
0.718 |
|
| 2020 |
Kang T, Yau C, Wong CK, Sanborn JZ, Newton Y, Vaske C, Benz SC, Krings G, Camarda R, Henry JE, Stuart J, Powell M, Benz CC. A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. Breast Cancer Research : Bcr. 22: 81. PMID 32736587 DOI: 10.1186/S13058-020-01322-6 |
0.703 |
|
| 2020 |
Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. Transcriptomic silencing as a potential mechanism of treatment resistance. Jci Insight. 5. PMID 32493840 DOI: 10.1172/Jci.Insight.134824 |
0.779 |
|
| 2020 |
Jaber MI, Song B, Taylor C, Vaske CJ, Benz SC, Rabizadeh S, Soon-Shiong P, Szeto CW. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival. Breast Cancer Research : Bcr. 22: 12. PMID 31992350 DOI: 10.1186/S13058-020-1248-3 |
0.618 |
|
| 2020 |
Heskett MB, Sanborn JZ, Boniface C, Goode B, Chapman J, Garg K, Rabban JT, Zaloudek C, Benz SC, Spellman PT, Solomon DA, Cho RJ. Multiregion exome sequencing of ovarian immature teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated components. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 31911616 DOI: 10.1038/S41379-019-0446-Y |
0.721 |
|
| 2020 |
Benz SC, Beziaeva L, Jaber M, Rabizadeh S, Szeto C. Highly accurate automated tissue classification using deep learning on digital pathology images: A novel tool for resolving conflicts in diagnosis. Journal of Clinical Oncology. 38: 3578-3578. DOI: 10.1200/Jco.2020.38.15_Suppl.3578 |
0.597 |
|
| 2020 |
Szeto C, Veerapaneni S, Parulkar R, Reddy SK, Rabizadeh S, Benz SC. Effect of chemokine signaling signatures on resolving discrepancy between TMB and checkpoint expression. Journal of Clinical Oncology. 38: 3131-3131. DOI: 10.1200/Jco.2020.38.15_Suppl.3131 |
0.608 |
|
| 2020 |
Fasching PA, Denkert C, Benz S, Weber KE, Szeto C, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, Mackelenbergh Mv, Rabizadeh S, et al. Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd5-08 |
0.641 |
|
| 2020 |
Szeto C, Denkert C, Fasching PA, Benz S, Weber KE, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, Mackelenbergh Mv, Rabizadeh S, et al. Abstract P6-10-04: Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-10-04 |
0.592 |
|
| 2020 |
Raj-Kumar P, Sturtz LA, Kovatich AJ, Deyarmin B, Hooke JA, Fantacone-Campbell L, Praveen-Kumar A, Liu J, Craig J, Kvecher L, Kane J, Melley J, Somiari S, Benz SC, Golovato J, et al. Abstract P6-06-09: Evaluation of laser microdissected primary breast tumors for RNA Seq over bulk processing and validated with cohort control Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-06-09 |
0.496 |
|
| 2020 |
Benz CC, Kang T, Yau C, Wong C, Newton Y, Vaske C, Benz SC, Krings G, Camarda R, Henry JE, Stuart J, Powell M. Abstract P3-08-20: The normal breastActivetranscriptome associated with future breast cancer risk is driven by a dysregulated adipocyte microenvironment Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-08-20 |
0.36 |
|
| 2019 |
Lee KL, Benz SC, Hicks KC, Nguyen A, Gameiro SR, Palena C, Sanborn JZ, Su Z, Ordentlich P, Rohlin L, Lee JH, Rabizadeh S, Soon-Shiong P, Niazi K, Schlom J, et al. Efficient tumor clearance and diversified immunity through neoepitope vaccines and combinatorial immunotherapy. Cancer Immunology Research. PMID 31292145 DOI: 10.1158/2326-6066.Cir-18-0620 |
0.693 |
|
| 2019 |
North JP, Solomon DA, Golovato J, Bloomer M, Benz SC, Cho RJ. Loss of ZNF750 in ocular and cutaneous sebaceous carcinomas. Journal of Cutaneous Pathology. PMID 31148199 DOI: 10.1111/Cup.13516 |
0.305 |
|
| 2019 |
Szeto C, Garner C, Kazmierczak K, Vaske CJ, Benz SC, Reddy SK. CMS subtypes characterized by high TMB shows immunosuppressive microenvironment that implies resistance to immunotherapy. Journal of Clinical Oncology. 37: 610-610. DOI: 10.1200/Jco.2019.37.4_Suppl.610 |
0.628 |
|
| 2019 |
Szeto C, Kazmierczak K, Chambers A, Kim YJ, Nguyen A, Tan IB, Benz SC, Vaske CJ. Comprehensive -omic analysis of 152 CRC patients allows greater subclassification than CMS or sidedness alone. Journal of Clinical Oncology. 37: 601-601. DOI: 10.1200/Jco.2019.37.4_Suppl.601 |
0.633 |
|
| 2019 |
Szeto C, Veerapaneni S, Kazmierczak K, Benz SC, Reddy SK, Yan D. Comprehensive profiling of immune landscape in gastrointestinal (GI) and head and neck (HN) cancers via computational deconvolution. Journal of Clinical Oncology. 37: 579-579. DOI: 10.1200/Jco.2019.37.4_Suppl.579 |
0.634 |
|
| 2019 |
Newton Y, Golovato J, Tan IB, Lam JYC, Yu G, Koo S, Chua C, Yeong JPS, Ping C, Skanderup A, Göke J, Johnson M, Rabizadeh S, Sanborn JZ, Benz SC, et al. Genomic and immune infiltration differences between MSI and MSS GI tumors. Journal of Clinical Oncology. 37: 528-528. DOI: 10.1200/Jco.2019.37.4_Suppl.528 |
0.778 |
|
| 2019 |
Parulkar R, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kato S, Kurzrock R, Szeto C. Evidence for selective silencing of MHC-binding neoepitopes to avoid immune surveillance. Journal of Clinical Oncology. 37: 2591-2591. DOI: 10.1200/Jco.2019.37.15_Suppl.2591 |
0.595 |
|
| 2019 |
Raj-Kumar P, Sturtz LA, Kovatich AJ, Deyarmin B, Hooke JA, Fantacone-Campbell L, Praveen-Kumar A, Liu J, Craig J, Kvecher L, Kane J, Melley J, Somiari S, Benz SC, Golovato J, et al. Abstract 3402: Evaluation of laser microdissected primary breast tumors for RNA-Seq over bulk processing Cancer Research. 79: 3402-3402. DOI: 10.1158/1538-7445.Am2019-3402 |
0.489 |
|
| 2019 |
Kang T, Yau C, Benz S, Krings G, Camarda R, Henry JE, Powell M, Benz CC. Abstract 3314: Normal breast tissue at risk for cancer development: A breast cancer initiating role for mammary adipocytes Cancer Research. 79: 3314-3314. DOI: 10.1158/1538-7445.Am2019-3314 |
0.377 |
|
| 2018 |
Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, ... ... Benz SC, et al. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Science Translational Medicine. 10. PMID 30135250 DOI: 10.1126/Scitranslmed.Aas9668 |
0.404 |
|
| 2018 |
Givechian KB, Wnuk K, Garner C, Benz S, Garban H, Rabizadeh S, Niazi K, Soon-Shiong P. Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. Npj Genomic Medicine. 3: 14. PMID 29928512 DOI: 10.1038/S41525-018-0054-7 |
0.456 |
|
| 2018 |
North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nature Communications. 9: 1894. PMID 29760388 DOI: 10.1038/S41467-018-04008-Y |
0.697 |
|
| 2018 |
Rabizadeh S, Garner C, Sanborn JZ, Benz SC, Reddy S, Soon-Shiong P. Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer. Oncotarget. 9: 19223-19232. PMID 29721196 DOI: 10.18632/oncotarget.24973 |
0.742 |
|
| 2018 |
Schwartz S, Tian Y, Cecchi F, Nguyen A, Kim YJ, Goh B, Chew MH, Tang CL, Toh E, Skanderup A, Koo S, Chua CWL, Leow WQ, Tan IB, Vaske CJ, ... ... Benz SC, et al. The prognostic role of microsatellite status, tumor mutational burden, and protein expression in CRC. Journal of Clinical Oncology. 36: 572-572. DOI: 10.1200/Jco.2018.36.4_Suppl.572 |
0.398 |
|
| 2018 |
Garner C, Reddy S, Sanborn JZ, Benz SC, Soon-Shiong P, Rabizadeh S. Tumor-normal sequencing to reveal frequency of false positive error rates with tumor-only sequencing in GI cancers and with RNA sequencing as a new standard of precision molecular profiling. Journal of Clinical Oncology. 36: 224-224. DOI: 10.1200/Jco.2018.36.4_Suppl.224 |
0.757 |
|
| 2018 |
Nguyen A, Sanborn JZ, Vaske CJ, Rabizadeh S, Tan IB, Benz SC. Validation of omics based MSI calling to improve upon traditional methods of MSI detection. Journal of Clinical Oncology. 36: e15663-e15663. DOI: 10.1200/Jco.2018.36.15_Suppl.E15663 |
0.641 |
|
| 2018 |
Tan IB, Nguyen A, Vaske CJ, Szeto C, Newton Y, Becht E, Yeong JPS, Benz SC, Thangaraju S, Lim B, Ho D, Lim KHT, Chua CWL, Mathew R, Tang CL, et al. RNA-Seq analyses of immune cell-type enrichments in 158 Asian colorectal cancers (CRCs). Journal of Clinical Oncology. 36: e15597-e15597. DOI: 10.1200/Jco.2018.36.15_Suppl.E15597 |
0.591 |
|
| 2018 |
Gasparini E, Cecchi F, di Cicilia R, Kuhn E, Falco G, Ferrari G, Foroni M, Tamagnini I, Bassano C, Tian Y, Benz SC, Hembrough TA, Bisagni A. Predicting pathological complete response (pCR) to neoadjuvant trastuzumab in patients with breast cancer using HER2 mass spectrometry. Journal of Clinical Oncology. 36: e12643-e12643. DOI: 10.1200/Jco.2018.36.15_Suppl.E12643 |
0.423 |
|
| 2018 |
Thyparambil SP, Kim YJ, Chambers A, Yan D, SELLAPPAN S, Gong C, Sedgewick A, Newton Y, Sanborn JZ, Vaske CJ, Benz SC, Cecchi F, Kang H, Hembrough TA. Comprehensive proteomic and genomic profiling to identify therapeutic targets in adenoid cystic carcinoma. Journal of Clinical Oncology. 36: 6053-6053. DOI: 10.1200/Jco.2018.36.15_Suppl.6053 |
0.711 |
|
| 2018 |
Denkert C, Untch M, Benz SC, Weber K, Golovato J, Budczies J, Nekljudova V, Stickeler E, Parulkar R, Schneeweiss A, Jackisch C, Sanborn JZ, Conrad B, Wiebringhaus H, Huober JB, et al. Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial. Journal of Clinical Oncology. 36: 574-574. DOI: 10.1200/Jco.2018.36.15_Suppl.574 |
0.718 |
|
| 2018 |
Schwartz C, Little J, Vaske CJ, Benz SC, Soon-Shiong P, Rabizadeh S, Sanborn JZ. The NantOmics Pharmacogenomics Test: An integrative panomic approach to pharmacogenomics screening. Journal of Clinical Oncology. 36: 2575-2575. DOI: 10.1200/Jco.2018.36.15_Suppl.2575 |
0.635 |
|
| 2018 |
Nguyen A, Garner C, Reddy SK, Sanborn JZ, Benz SC, Seery TE, Rabizadeh S. Three-fold overestimation of tumor mutation burden using 248 gene panel versus whole exome. Journal of Clinical Oncology. 36: 12117-12117. DOI: 10.1200/Jco.2018.36.15_Suppl.12117 |
0.711 |
|
| 2018 |
Pal SK, Vanderwalde AM, Szeto C, Benz SC, Sanborn JZ, Vaske CJ, Reddy SK, Hamid O. Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression. Journal of Clinical Oncology. 36: 12113-12113. DOI: 10.1200/Jco.2018.36.15_Suppl.12113 |
0.735 |
|
| 2018 |
Benz C, Yau C, Benz S, Krings G, Powell M. Abstract P3-10-05: Normal breast biopsies reveal an "active" transcriptome associating with higher breast cancer risk (Gail) scores and increased IGF-1 growth factor expression Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-10-05 |
0.368 |
|
| 2018 |
Thyparambil SP, Kim YJ, Chambers AG, Yan D, Sellappan S, Sedgewick AJ, Newton Y, Sanborn JZ, Vaske CJ, Benz SC, Cecchi F, Kang H, Hembrough TA. Abstract 778: Potential drug targets for adenoid cystic carcinoma elucidated by proteogenomic analysis Cancer Research. 78: 778-778. DOI: 10.1158/1538-7445.Am2018-778 |
0.473 |
|
| 2017 |
Szeto C, Parulkar R, Sedgewick A, Benz SC, Cecchi F, Hembrough TA, Vaske CJ, Sanborn Z, Rabizadeh S, Mahen E, Burton K, Soon-Shiong P, Kuderer NM, Senecal FM, Blau S, et al. Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer. Journal of Clinical Oncology. 35: 1093-1093. DOI: 10.1200/JCO.2017.35.15_suppl.1093 |
0.423 |
|
| 2017 |
Kumar PKR, Liu T, Sturtz LA, Kovatich A, Gritsenko MA, Petyuk VA, Deyarmin B, Sridhara V, Craig J, McDermott JE, Shukla AK, Moore RJ, Monroe ME, Webb-Robertson BM, Hooke JA, ... ... Benz SC, et al. Abstract 3372: Differential exon usage in the HER2 subtype of breast cancer identified with RNA-seq and proteomic data Cancer Research. 77: 3372-3372. DOI: 10.1158/1538-7445.Am2017-3372 |
0.432 |
|
| 2017 |
Sridhara V, Liu T, Gritsenko MA, Sturtz LA, Kovatich AJ, Petyuk VA, Deyarmin B, McDermott JE, Shukla AK, Moore RJ, Monroe ME, Webb-Robertson BM, Hooke JA, Fantacone-Campbell L, Kumar PKR, ... ... Benz SC, et al. Abstract 213: Integrated proteogenomic analysis of laser capture microdissected breast tumors Cancer Research. 77: 213-213. DOI: 10.1158/1538-7445.Am2017-213 |
0.337 |
|
| 2017 |
Cho R, McMullen K, Solomon D, Benz S, Golovato J, Goode B, North J. 114 The genomic landscape of sebaceous cell carcinoma Journal of Investigative Dermatology. 137: S19. DOI: 10.1016/J.Jid.2017.02.128 |
0.313 |
|
| 2016 |
Nguyen A, Sanborn JZ, Vaske CJ, Rabizadeh S, Niazi K, Soon-Shiong P, Benz SC. Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy targets in breast cancer patients by HLA typing and predicting MHC presentation from whole genome and RNA sequencing data. Journal of Clinical Oncology. 34: 11606-11606. DOI: 10.1200/Jco.2016.34.15_Suppl.11606 |
0.721 |
|
| 2016 |
Szeto CW, Benz S, Vaske C. Abstract 44: Building patient-specific predictors of drug responses from cell line genomics Clinical Cancer Research. 22: 44-44. DOI: 10.1158/1557-3265.Pmsclingen15-44 |
0.434 |
|
| 2016 |
Benz S, Sanborn JZ, Hensley NS, Hembrough T, Vaske CJ, Burrows J, Rabizadeh S, Royston I, Soon-Shiong P. Abstract 25: Whole genome sequencing and quantitative proteomics reveal HPV integration and HER2 overexpression in a patient with cervical cancer: Comprehensive omics analysis driving clinical treatment decisions Clinical Cancer Research. 22: 25-25. DOI: 10.1158/1557-3265.Pmsclingen15-25 |
0.501 |
|
| 2015 |
Yau C, Meyer L, Benz S, Vaske C, Scott G, Egan B, Labhart P, Pourmand N, Benz CC. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index. Breast Cancer Research and Treatment. 154: 23-32. PMID 26456572 DOI: 10.1007/S10549-015-3589-7 |
0.435 |
|
| 2015 |
Favero F, McGranahan N, Salm M, Birkbak NJ, Sanborn JZ, Benz SC, Becq J, Peden JF, Kingsbury Z, Grocok RJ, Humphray S, Bentley D, Spencer-Dene B, Gutteridge A, Brada M, et al. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 880-7. PMID 25732040 DOI: 10.1093/Annonc/Mdv127 |
0.66 |
|
| 2015 |
Rabizadeh S, Benz SC, Burrows J, Hembrough TA, Sanborn JZ, Vaske CJ, Soon-Shiong P. Genomics, transcriptomics, and proteomics in the clinical setting: Integrating whole genome and RNA sequencing with quantitative proteomics to better inform clinical treatment selection. Journal of Clinical Oncology. 33: 11093-11093. DOI: 10.1200/Jco.2015.33.15_Suppl.11093 |
0.733 |
|
| 2015 |
Benz SC, Rabizadeh S, Sanborn JZ, Vaske CJ, Palmer GA, Soon-Shiong P. Protein expression by genetic mutations identified in gene panels (hotspots) and efficacy of targeted treatments. Journal of Clinical Oncology. 33: 11005-11005. DOI: 10.1200/Jco.2015.33.15_Suppl.11005 |
0.728 |
|
| 2015 |
Yau C, Garay J, Benz S, Gray J, Park B, Benz CC. Abstract 1084: An EMT-like gene expression profile differentiates helical from kinase domain PIK3CA mutations Cancer Research. 75: 1084-1084. DOI: 10.1158/1538-7445.Am2015-1084 |
0.409 |
|
| 2014 |
Dave B, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P, Yu KD, Shao Z, Li X, Gilcrease M, Lai Z, Chen Y, Huang TH, Shen H, Liu X, et al. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proceedings of the National Academy of Sciences of the United States of America. 111: 8838-43. PMID 24876273 DOI: 10.1073/Pnas.1320769111 |
0.474 |
|
| 2014 |
Rabizadeh S, Benz SC, Sanborn JZ, Vaske CJ, Soon-Shiong P. A comprehensive analysis of molecular profiles across over 10,000 tumor and germ-line exomes across more than 20 tumor types: Novel mechanisms and targets for clinical treatment. Journal of Clinical Oncology. 32: 11031-11031. DOI: 10.1200/Jco.2014.32.15_Suppl.11031 |
0.759 |
|
| 2014 |
Yau C, Benz S, Vaske C, Ng S, Stuart J, Benz CC. Abstract 4165: Differential pathway activation associated with domain-specific PIK3CA mutations Cancer Research. 74: 4165-4165. DOI: 10.1158/1538-7445.Am2014-4165 |
0.403 |
|
| 2014 |
Vinayak S, Benz SC, Vaske CJ, Telli ML, Ford JM. Abstract 2826: Multi-omic profiling to predict response to gemcitabine/ carboplatin (GC) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer using a pathway-based approach Cancer Research. 74: 2826-2826. DOI: 10.1158/1538-7445.Am2014-2826 |
0.504 |
|
| 2013 |
Sedgewick AJ, Benz SC, Rabizadeh S, Soon-Shiong P, Vaske CJ. Learning subgroup-specific regulatory interactions and regulator independence with PARADIGM. Bioinformatics (Oxford, England). 29: i62-70. PMID 23813010 DOI: 10.1093/Bioinformatics/Btt229 |
0.47 |
|
| 2013 |
Wong CK, Vaske CJ, Ng S, Sanborn JZ, Benz SC, Haussler D, Stuart JM. The UCSC Interaction Browser: multidimensional data views in pathway context. Nucleic Acids Research. 41: W218-24. PMID 23748957 DOI: 10.1093/Nar/Gkt473 |
0.727 |
|
| 2013 |
Yau C, Meyer L, Benz S, Vaske C, Scott G, Egan B, Labhart P, Mitchell E, Pourmand N, Benz C. Abstract 1813: FOXM1 target genes associated with cell cycle regulation predict breast cancer metastatic outcome. Cancer Research. 73: 1813-1813. DOI: 10.1158/1538-7445.Am2013-1813 |
0.437 |
|
| 2012 |
Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, Spellman P, Waldman F, Benz CC. Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells? Breast Cancer Research and Treatment. 136: 693-703. PMID 23104223 DOI: 10.1007/S10549-012-2290-3 |
0.477 |
|
| 2012 |
Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 2724-9. PMID 22003129 DOI: 10.1073/Pnas.1018854108 |
0.758 |
|
| 2012 |
Szeto CW, Sokolov A, Benz S, Stuart J, Haussler D. Abstract 5085: TopModel: An online resource for predictive models in cancer Cancer Research. 72: 5085-5085. DOI: 10.1158/1538-7445.Am2012-5085 |
0.599 |
|
| 2012 |
Sanborn JZ, Vaske CJ, Benz SC. Abstract 3982: Cancer genome sequencing analysis, storage, discovery and delivery Cancer Research. 72: 3982-3982. DOI: 10.1158/1538-7445.Am2012-3982 |
0.475 |
|
| 2012 |
Ng S, Thusberg J, Benz S, Vaske C, Ellrott K, Zhu J, Yau C, Collisson E, Mooney S, Benz C, Haussler D, Stuart J. Abstract 2985: Predicting the impact of mutations in cancer using an integrated pathway approach Cancer Research. 72: 2985-2985. DOI: 10.1158/1538-7445.Am2012-2985 |
0.595 |
|
| 2012 |
Saghatchian M, Mittempergher L, Michiels S, Wolf D, Canisius S, Dessen P, Delaloge S, Lazar V, Benz S, Roepman P, Glas A, Tursz T, Bernards R, Veer Lv. Abstract P4-09-05: Microarray anlyses of breast cancers identify CH25H, a cholesterol gene, as a potential marker and target for late metastatic reccurences. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-09-05 |
0.409 |
|
| 2011 |
Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, Vaske CJ, Goldman M, Smith KE, Kuhn RM, Karolchik D, Kent WJ, Stuart JM, Haussler D, Zhu J. The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Research. 39: D951-9. PMID 21059681 DOI: 10.1093/Nar/Gkq1113 |
0.798 |
|
| 2011 |
Zhu J, Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Goldman M, Meyer L, Vaske C, Collisson E, Stuart J, Haussler D. Abstract 4985: The UCSC Cancer Genomics Browser Cancer Research. 71: 4985-4985. DOI: 10.1158/1538-7445.Am2011-4985 |
0.723 |
|
| 2011 |
Szeto CW, Zhu J, Durbin J, Benz S, Vaske C, Stuart J, Haussler D. Abstract 43: Using matrix factorization to discover clinically-relevant molecular signatures across cancers Cancer Research. 71: 43-43. DOI: 10.1158/1538-7445.Am2011-43 |
0.604 |
|
| 2011 |
Saghatchian M, Mittempergher L, Michiels S, Casinius S, Glas A, Lazar V, Roepman P, Dessen P, Benz S, Piccart M, Delaloge S, Veer Lv. S1-6: Characterization of Breast Cancer Distant Metastasis Based on Outcome over Time Using a Gene Expression Profiling Approach and Identification of Pathway Activities of Late Relapse. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S1-6 |
0.394 |
|
| 2010 |
Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (Oxford, England). 26: i237-45. PMID 20529912 DOI: 10.1093/Bioinformatics/Btq182 |
0.788 |
|
| 2010 |
Benz SC, Vaske C, Ng S, Sanborn JZ, Zhu J, Haussler D, Stuart J. Abstract 4905: Patient-specific pathway analysis using PARADIGM identifies key activities in multiple cancers Cancer Research. 71: 4905-4905. DOI: 10.1158/1538-7445.Am2011-4905 |
0.64 |
|
| 2010 |
Christopher S, Benz S, Vaske C, Sanborn JZ, Zhu J, Stuart J, Haussler D. Abstract 2001: Non-negative matrix factorization (NMF) as a clinical classifier: An example with chemotherapy response in ovarian cancer Cancer Research. 70: 2001-2001. DOI: 10.1158/1538-7445.Am10-2001 |
0.551 |
|
| 2009 |
Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T. The UCSC Cancer Genomics Browser. Nature Methods. 6: 239-40. PMID 19333237 DOI: 10.1038/Nmeth0409-239 |
0.792 |
|
| 2009 |
Zhu J, Sanborn J, Wang T, Hsu F, Benz S, Szeto C, Esserman L, Haussler D. UCSC cancer genomics browser. Cancer Research. 69: 2022. DOI: 10.1158/0008-5472.Sabcs-2022 |
0.724 |
|
| 2006 |
Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Breast cancer growth prevention by statins. Cancer Research. 66: 8707-14. PMID 16951186 DOI: 10.1158/0008-5472.Can-05-4061 |
0.381 |
|
| Show low-probability matches. |